Abstract
Primary B cells from B cell chronic lymphocytic leukaemia (B-CLL) were resistant to the novel selective cytotoxic agent, TNF-related apoptosis-inducing ligand (TRAIL). Low levels of the death-inducing TRAIL receptors, TRAIL-R1 and TRAIL-R2 but not the putative ‘decoy’ receptors, TRAIL-R3 and TRAIL-R4, were expressed on the surface of B-CLL cells. Resistance to TRAIL was upstream of caspase-8 activation, as little or no caspase-8 was processed in TRAIL-treated B-CLL cells. Low levels of a TRAIL death-inducing signalling complex (DISC) were formed in these cells, accompanied by the recruitment of endogenous FADD, caspase-8 and c-FLIPL but not c-FLIPS. Both caspase-8 and c-FLIPL were cleaved to form two stable intermediates of ∼43 kDa, which remained associated with the DISC. Caspase-8 was not further processed to its active heterotetramer. Thus the resistance of B-CLL cells to TRAIL may be due partly to low surface expression of the death receptors resulting in low levels of DISC formation and also to the high ratio of c-FLIPL to caspase-8 within the DISC, which would prevent further activation of caspase-8. Our results highlight the possibility of sensitising B-CLL cells to TRAIL by modulation of c-FLIP levels or by upregulation of surface expression of death receptors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- B-CLL:
-
B-cell chronic lymphocytic leukaemia
- Bis:
-
bisindolylmaleimide
- DISC:
-
death-inducing signalling complex
- FADD:
-
Fas-associated death domain protein
- c-FLIP:
-
cellular FLICE inhibitory protein
- GAPDH:
-
glyceraldehyde-3-phosphate dehydrogenase
- TRAIL:
-
Tumour necrosis factor-related apoptosis-inducing ligand
- PS:
-
phosphatidylserine
- TRAIL-R:
-
TRAIL receptor
- XIAP:
-
X-linked inhibitor of apoptosis protein
References
Ahmad M, Shi Y . 2000 Oncogene 19: 3363–3371
Almond JB, Snowden RT, Hunter A, Cain K, Cohen GM . 2001 Leukemia 15: 1388–1397
Ashkenazi A, Dixit VM . 1998 Science 281: 1305–1308
Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Herbert A, De Forge L, Koumeris IL, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH . 1999 J. Clin. Invest. 104: 155–162
Bodmer J-L, Holler H, Reynard S, Inciguerra P, Schneider P, Jou P, Blenis J, Tschopp J . 2000 Nature Cell Biol. 2: 241–243
Boldin MP, Goncharov TM, Goltsev YV, Wallach D . 1996 Cell 85: 803–815
Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM . 1995 Cell 81: 505–512
Deveraux QL, Reed JC . 1999 Genes Dev. 13: 239–252
Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC . 1999 EMBO J. 18: 5242–5251
Fulda S, Meyer E, Debatin K-M . 2000 Cancer Res. 60: 3947–3956
Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ . 1998 J. Immunol. 161: 2833–2840
Griffith TS, Rauch CT, Smolak PJ, Waugh JY, Bojani N, Lynch DH, Smith CA, Goodwin RG, Kubin HZ . 1999 J. Immunol. 162: 2597–2605
Harper N, Farrow SN, Kaptein A, Cohen GM, MacFarlane M . 2001 J. Biol. Chem. 276: 34743–34752
Hennino A, Berard M, Casamayor-Palleja M, Krammer PH, Defrance T . 2000 J. Immunol. 165: 3023–3030
Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattman C, Rimoldi D, French LE, Tschopp J . 1997 Nature 388: 190–195
Jiang Y, Woronicz JD, Liu W, Goeddel DV . 1999 Science 283: 543–546
Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC . 2000 Nat. Med. 6: 564–567
Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S . 1999 Cancer Res. 59: 734–741
Keogh SA, Walczak H, Bouchier-Hayes L, Martin SJ . 2000 FEBS Lett. 471: 93–98
Kim K, Fisher MJ, Xu S-Q, El-Deiry WS . 2000 Clin. Cancer Res. 6: 335–346
King D, Pringle JH, Hutchinson M, Cohen GM . 1998 Leukemia 12: 1553–1560
Kirchoff S, Müller WW, Krueger A, Schmitz I, Krammer PH . 2000 J. Immunol. 165: 6293–6300
Kischkel FC, Hellbardt S, Behrmann I, Germer M, Krammer PH, Peter ME . 1995 EMBO J. 14: 5579–5588
Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A . 2000 Immunity 12: 611–620
Krueger A, Schmitz I, Baumann S, Krammer PH, Kirchoff S . 2001 J. Biol. Chem. 276: 20633–20640
Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D, Ashkenazi A . 2001 Nat. Med. 7: 383–385
Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, Park GS, Dong SH, Pi JH, Kim CS, Lee JY, Yoo NJ . 1999 Oncogene 18: 3754–3760
Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB, Krammer PH, Walczak H . 2000 Cancer Res. 60: 553–559
MacFarlane M, Merrison W, Dinsdale D, Cohen GM . 2000 J. Cell Biol. 148: 1239–1254
Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD, Ashkenazi A . 1996 Curr. Biol. 6: 750–752
Mori S, Murakami-Mori K, Nakamura S, Ashkenazi A, Bonavida B . 1999 J. Immunol. 162: 5616–5623
Munshi A, Pappas G, Honda T, McDonnell TJ, Younes A, Li Y, Meyn RE . 2001 Oncogene 20: 3757–3765
Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter HE, Dixit VM . 1996 Cell 85: 817–827
Nesterov A, Ivashchenko Y, Kraft AS . 2002 Oncogene 21: 1135–1140
O'Brien KAF, Smith LL, Cohen GM . 1987 Toxic. In Vitro 1: 85–90
Pai SI, Wu GS, Özören N, Wu L, Jen J, Sidransky D, El-Deiry WS . 1998 Cancer Res. 58: 3513–3518
Plumas J, Jacob M-C, Chaperot L, Molens JP, Sotto JJ, Bensa JC . 1998 Blood 91: 2875–2885
Rasper DM, Vaillancourt JP, Hadano S, Houtzager VM, Seidon I, Keen SL, Tawa P, Xanthoudakis S, Nasir J, Martindale D, Koop BF, Peterson EP, Thornberry NA, Huang J, Lenardo MT, Hayden MR, Roy S, Nicholson DW . 1998 Cell Death Differ. 5: 271–288
Rozman C, Montserrat E . 1995 New Engl. J. Med. 333: 1052–1057
Scaffidi C, Medema JP, Krammer PH, Peter ME . 1997 J. Biol. Chem. 272: 26953–26958
Scaffidi C, Schmitz I, Krammer PH, Peter ME . 1999 J. Biol. Chem. 274: 1541–1548
Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, Kadin ME, Cabanillas F, Andreeff M, Younhes A . 1997 Br. J. Haematol. 99: 618–624
Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, Walczak H . 2000 Immunity 12: 599–609
Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM . 1999 J. Biol. Chem. 274: 5053–5060
Tepper CG, Seldin MF . 1999 Blood 94: 1727–1737
Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH . 1999 Nat. Med. 5: 157–163
Walczak H, Bouchon A, Stahl H, Krammer PH . 2000 Cancer Res. 60: 3051–3057
Wang C-Y, Mayo MW, Korneluk RG, Goeddel DV, Baldwin ASJ . 1998 Science 281: 1680–1683
Wang D, Freeman GJ, Levine H, Ritz J, Robertson MJ . 1997 Br. J. Haematol. 97: 409–417
Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA . 1995 Immunity 3: 673–682
Willems F, Amraoui Z, Vanderheyde N, Verhasselt V, Aksoy E, Scaffidi C, Peter ME, Krammer PH, Goldman M . 2000 Blood 95: 3478–3482
Xerri L, Devilard E, Hassoun J, Haddad P, Birg F . 1997 Leukemia 11: 1868–1877
Xerri L, Bouabdallah R, Devilard E, Hassoun J, Stoppa AM, Birg F . 1998 Br. J. Cancer 78: 225–232
Yeh WC, Pompa JL, McCurrach ME, Shu HB, ELia AJ, Shahinian A, Ng M, Wakeham A, Khoo W, Mitchell K, El-Diery WS, Lowe SW, Goeddel DV, Mak TW . 1998 Science 279: 1954–1958
Zhang J, Winoto A . 1996 Mol. Cell. Biol. 16: 2756–2763
Zhou T, Song L, Yang P, Wang Z, Lui D, Jope RS . 1999 Nat. Med. 5: 42–48
Acknowledgements
We thank Immunex for supplying LZ-TRAIL and the TRAIL receptor antibodies, Dr D Nicholson for c-FLIP antibody and Dr R Waleska for assistance in retrieval of clinical information. This work was supported in part by the Medical Research Council and a grant from the European Union (Grant # QLG1-1999-00739) (to GM Cohen).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
MacFarlane, M., Harper, N., Snowden, R. et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 21, 6809–6818 (2002). https://doi.org/10.1038/sj.onc.1205853
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205853
Keywords
This article is cited by
-
Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia
Nature Communications (2021)
-
The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma
Cell Death & Disease (2019)
-
Genetic association between TRAIL-R1 Thr209Arg and cancer susceptibility
Scientific Reports (2015)
-
Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL
Breast Cancer Research (2011)
-
Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist
Apoptosis (2011)